Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The purpose is to demonstrate that vasoreactivity of patients with septic shock evaluated
with dose-response curve is diminished in septic shock and ameliorated by activated protein C
(APC).
This amelioration is correlated to decrease of inflammation, decrease of reactive oxygen
species (ROS) markers and increase of circulating catecholamines.
Phase:
Phase 4
Details
Lead Sponsor:
Central Hospital, Nancy, France
Treatments:
Drotrecogin alfa activated Oxymetazoline Phenylephrine Protein C